Ewing Sarcoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Ewing Sarcoma – Drugs In Development, 2023’, provides an overview of the Ewing Sarcoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma
- The report reviews pipeline therapeutics for Ewing Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ewing Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Ewing Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ewing Sarcoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Aadi Bioscience IncAbbVie Inc
Actuate Therapeutics Inc
ADC Therapeutics SA
Altay Therapeutics Inc
Amgen Inc
AntiCancer Inc
Aptadel Therapeutics SL
Atlanthera
Aurora BioPharma Inc
Bayer AG
Beijing zhikangbo Medical Oncology Research Co Ltd
Bellvitge Biomedical Research Institute
BioAtla Inc
BioMarck Pharmaceuticals Ltd
Bristol-Myers Squibb Co
CancerVAX Inc
Carrick Therapeutics Ltd
Cebiotex SL
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Children's National Research Institute
Chimerix Inc
Cornerstone Pharmaceuticals Inc
Diatheva srl
Edison Oncology Holding Corp
Eisai Co Ltd
Eli Lilly and Co
EntreChem SL
Esperas Pharma Inc
Exelixis Inc
Fusion Pharmaceuticals Inc
GAiA BioMedicine Inc
Gate2Brain SL
Gibson Oncology LLC
Gradalis Inc
Hutchison MediPharma Ltd
Inhibrx Inc
Ipsen SA
Iterion Therapeutics Inc
Japan Agency for Medical Research and Development
Jazz Pharmaceuticals Plc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSK Therapeutics Inc
Kronos Bio Inc
Lantern Pharma Inc
LintonPharm Co Ltd
Lirum Therapeutics Inc
MacroGenics Inc
Mana Therapeutics Inc
MediaPharma SRL
Medosome Biotec LLC
Merck & Co Inc
MERLIN Biotech LLC
NanoValent Pharmaceuticals Inc
National Cancer Institute US
Nationwide Children's Hospital
Natsar Pharmaceuticals Inc
Nektar Therapeutics
New York Medical College
Ohara Pharmaceutical Co Ltd
Ohio State University
Oncology Pharma Inc
Oncomatryx Biopharma SL
OrphAI Therapeutics Inc
Orphelia Pharma SAS
Peel Therapeutics Inc
Pfizer Inc
Pharma Mar SA
PharmaEngine Inc
Provectus Biopharmaceuticals Inc
QSAM Therapeutics Inc
Rakovina Therapeutics Inc
Salarius Pharmaceuticals Inc
SELLAS Life Sciences Group Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Stanford University School of Medicine
Sumitomo Dainippon Pharma Oncology
Inc
Syros Pharmaceuticals Inc
Theranano LLC
Tyme Inc
University Hospital Tubingen
University of Miami
University of South Australia
Virogin Biotech Ltd